Your session is about to expire
← Back to Search
Robotic Arm-assisted Surgery
Robotic Arm-Assisted Surgery for Hip Conditions
N/A
Waitlist Available
Led By Benjamin G Domb, MD
Research Sponsored by American Hip Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up preoperatively and postoperatively at 6 weeks and 1 year
Awards & highlights
No Placebo-Only Group
Summary
This trial is testing a new robotic system to see how precise and accurate it is.
Who is the study for?
This trial is for adults over 18 needing hip replacement surgery due to conditions like Hip Dysplasia or Osteoarthritis. Participants must be able to follow post-surgery check-ups and sign a consent form. It's not for those with infections near the joint, BMI over 40, neuromuscular disorders, muscle atrophy, poor blood supply in the limb, Ankylosing spondylitis, or inadequate bone stock.
What is being tested?
The study tests the MAKO THA 4.0 System—a robotic arm-assisted device—to see how precise and accurate it is during hip replacement surgeries across multiple centers using new software.
What are the potential side effects?
While specific side effects are not listed for this device trial, typical risks of robotic-assisted surgery may include pain at the incision site, bleeding, infection risk similar to traditional surgery methods.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ preoperatively and postoperatively at 6 weeks and 1 year
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~preoperatively and postoperatively at 6 weeks and 1 year
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Computed Tomography scan. Placement accuracy of acetabular cup and femoral stem
Secondary study objectives
Forgotten Joint Score
Harris Hip Score
Hip Disability and Osteoarthritis Outcome Score
+3 moreAwards & Highlights
No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.
Trial Design
1Treatment groups
Experimental Treatment
Group I: Mako THA 4.0 groupExperimental Treatment1 Intervention
Hip system used: femoral stem (Accolade II), acetabular cup (Trident II or MDM if necessary), femoral head (ceramic or metal head compatible with Accolade II), acetabular insert (X3 Trident II or MDM liner when using MDM cup). Mako THA 4.0 software also will be used.
Find a Location
Who is running the clinical trial?
Hospital for Special Surgery, New YorkOTHER
250 Previous Clinical Trials
61,301 Total Patients Enrolled
26 Trials studying Osteoarthritis
4,295 Patients Enrolled for Osteoarthritis
American Hip InstituteLead Sponsor
6 Previous Clinical Trials
350 Total Patients Enrolled
Stryker OrthopaedicsIndustry Sponsor
78 Previous Clinical Trials
20,412 Total Patients Enrolled
13 Trials studying Osteoarthritis
2,678 Patients Enrolled for Osteoarthritis
Benjamin G Domb, MDPrincipal InvestigatorAmerican Hip Institute
1 Previous Clinical Trials
107 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- You currently have an infection or might have an infection in or around your joint.At least 18 years old.You have a body mass index (BMI) of over 40, which indicates severe obesity.You have a disorder that affects your muscles, or your limb has weak or damaged blood vessels.You have a medical condition called ankylosing spondylitis.You need to have a complete hip replacement surgery.Can and is willing to comply with the requirements for postoperative follow-up.You are still growing and developing physically.Your bones are not strong enough to support or properly attach the prosthesis.
Research Study Groups:
This trial has the following groups:- Group 1: Mako THA 4.0 group
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.